NTRA
Natera, Inc.
NTRA has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over NTRA overall, supported by stronger fundamentals and stronger modeled upside.
NTRA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NTRA's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NTRA PE Valuation
NTRA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NTRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NTRA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NTRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.13 | +$1.16 |
| Q2 2026 | -$1.35 | +$0.56 |
| Q1 2026 | -$1.62 | -$0.15 |
| Q4 2025 | -$1.52 | +$0.01 |
| Q3 2025 | -$2.29 | -$0.54 |
| Q2 2025 | -$1.91 | +$0.53 |
| Q1 2025 | -$1.47 | +$1.64 |
| Q4 2024 | -$1.53 | +$2.25 |
NTRA is still losing money, but far less than before: $1.13 per share over the past year, against $6.10 at its worst in mid-2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NTRA on earnings quality, reporting a profit while its opponent remains loss making.
NTRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $794M | +34% |
| Q2 2026 | $752.8M | +38% |
| Q1 2026 | $696.6M | +39% |
| Q4 2025 | $665.5M | +40% |
| Q3 2025 | $592.2M | +35% |
| Q2 2025 | $546.6M | +32% |
| Q1 2025 | $501.8M | +36% |
| Q4 2024 | $476.1M | +53% |
NTRA's revenue has grown year over year every quarter since late 2020: $794M last quarter, up 34% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8.6% | +7.9 points |
| Q2 2026 | -10% | +10 points |
| Q1 2026 | -13% | +2.4 points |
| Q4 2025 | -3.4% | +10 points |
| Q3 2025 | -16% | -7.5 points |
| Q2 2025 | -20% | -9.6 points |
| Q1 2025 | -16% | +4.4 points |
| Q4 2024 | -14% | +14 points |
NTRA's operating margin was −8.6% last quarter, up 7.9 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NTRA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NTRA on profitability, with a higher operating margin.
NTRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.3M | -86% |
| Q2 2026 | -$8.6M | -174% |
| Q1 2026 | $18M | -20% |
| Q4 2025 | $37.8M | +8.8% |
| Q3 2025 | $37M | +4.3% |
| Q2 2025 | $11.7M | +$19.4M |
| Q1 2025 | $22.6M | +239% |
| Q4 2024 | $34.8M | +$102.4M |
NTRA has burned cash in most quarters: $52M over the past year, down 51% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NTRA on cash flow, with more consistent year-over-year improvement.
NTRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +788K shares |
| 1 year | +5% | +6.9M shares |
| 3 years | +25% | +28.9M shares |
| 5 years | +56% | +51.5M shares |
| Available history | +107% | +74.5M shares |
NTRA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NTRA Net Leverage
NTRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NTRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 43.5 | Neutral |
NTRA's weekly RSI is 51 (neutral) and its Stochastic is 44 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NTRA PE vs Healthcare Sector
NTRA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NTRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $383.6 | 16% below |
| 20 week MA | $336.8 | 4.1% below |
| 50 week MA | $263.7 | 22% above |
| 100 week MA | $214.8 | 50% above |
| 200 week MA | $147.1 | 120% above |
NTRA has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 120% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NTRA on trend strength, trading above more of its moving averages.
NTRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.7 | $111.7 | +232% |
| 2021 | $111.7 | $93.8 | -16% |
| 2022 | $93.8 | $41.5 | -56% |
| 2023 | $41.5 | $62.6 | +51% |
| 2024 | $62.6 | $160.3 | +156% |
| 2025 | $160.3 | $233.7 | +46% |
| 2026 YTD | $233.7 | $322.9 | +38% |
NTRA's yearly returns have swung widely, from +232% in 2020 to −56% in 2022. It's up 38% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NTRA on returns for 2026, with the stronger performance.